Cellsway Receives €200,000 Investment from APY Ventures

APY Ventures has invested 200,000 Euros for Cellsway, which develops cancer diagnostics solutions. Cellsway's investment amount has reached 4 Million Euros with this investment. In addition to the investment, Cellsway received a total of 1 million Euros in grants from TÜBİTAK and European Union Funds. Cellsway, founded in 2015 as a spin-off of METU BioMEMS research group, focuses on the development of microfluidics and lab-on-a-chip systems for biomedical applications. The company's vision is to become a global player in the field of biomedical microsystems technology. The company's mission is to transform its know-how and patented technology into commercial products to provide innovative solutions to unmet needs in the field of cancer and to set the gold standard for cancer diagnosis and treatment.

Also See: What happened in the startup ecosystem this week?

Cellsway Improves Effective Solutions in Cancer Diagnosis

Cellsway is developing a liquid biopsy platform that utilises a simple blood sample to assist clinicians in cancer monitoring, treatment guidance and drug selection. In this platform, the patented microfluidic technology enables the rapid and efficient isolation of Circulating Tumour Cells (CTCs) from the blood sample, followed by the identification and characterisation of CTCs with the downstream analysis tests we have developed. Thus, clinicians are provided with clinically applicable data for cancer diagnosis, treatment selection and follow-up.